Ocugen Files 8-K: Corporate Changes and Financial Updates
Ticker: OCGN · Form: 8-K · Filed: Mar 20, 2024 · CIK: 1372299
| Field | Detail |
|---|---|
| Company | Ocugen, INC. (OCGN) |
| Form Type | 8-K |
| Filed Date | Mar 20, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, bylaws, financials
Related Tickers: OCGN
TL;DR
Ocugen 8-K filed: Corporate governance, bylaws, and financials updated as of March 15.
AI Summary
Ocugen, Inc. filed an 8-K on March 20, 2024, reporting events as of March 15, 2024. The filing primarily concerns amendments to its articles of incorporation or bylaws, changes in its fiscal year, and financial statements and exhibits. It also touches upon the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers.
Why It Matters
This filing indicates potential shifts in Ocugen's corporate structure, governance, or financial reporting, which could impact investors' understanding of the company's operations and future direction.
Risk Assessment
Risk Level: medium — Filings related to corporate governance, officer changes, and financial statements can signal significant internal shifts that may affect the company's strategic direction and financial health.
Key Players & Entities
- Ocugen, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- March 15, 2024 (date) — Date of Earliest Event Reported
- March 20, 2024 (date) — Date of Report
FAQ
What specific amendments were made to Ocugen, Inc.'s articles of incorporation or bylaws?
The filing indicates amendments to articles of incorporation or bylaws were made, but the specific details of these amendments are not provided in the provided text snippet.
Were there any changes to Ocugen, Inc.'s fiscal year?
The filing lists 'Change in Fiscal Year' as an item information, suggesting a potential change, but the specific details or confirmation of a change are not present in the provided text.
What are the key items reported under 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers'?
The filing indicates these items are reported, but the specific names of individuals, their roles, or details of compensatory arrangements are not included in the provided text.
What financial statements and exhibits are included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific content of these statements and exhibits is not detailed in the provided text snippet.
What is the exact date of the earliest event reported in this 8-K filing?
The exact date of the earliest event reported in this 8-K filing is March 15, 2024.
Filing Stats: 695 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2024-03-20 17:15:09
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share OCGN The Nasdaq
Filing Documents
- tm249388d1_8k.htm (8-K) — 28KB
- tm249388d1_ex3-1.htm (EX-3.1) — 7KB
- 0001104659-24-036775.txt ( ) — 206KB
- ocgn-20240315.xsd (EX-101.SCH) — 3KB
- ocgn-20240315_lab.xml (EX-101.LAB) — 33KB
- ocgn-20240315_pre.xml (EX-101.PRE) — 22KB
- tm249388d1_8k_htm.xml (XML) — 4KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 20, 2024, Ramesh Kumar, PhD, a member of the board of directors (the "Board of Directors") since 2019 notified Ocugen, Inc. (the "Company") that he will not stand for re-election as a director of the Company upon the expiration of his current term, which expires at the Company's 2024 Annual Meeting of Stockholders (the "Annual Meeting"). Class I directors of the Board of Directors, of which Mr. Kumar is a member, terms expire at the Annual Meeting and are up for re-election at the Annual Meeting. Dr. Kumar's refusal to stand for re-election was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. The Company thanks Dr. Kumar for his years of service as a director.
03. Amendments
Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On March 15, 2024, the Board of Directors of the Company approved an amendment (the "Bylaws Amendment") to the Second Amended and Restated Bylaws of the Company (the "Bylaws"), effective immediately. The Bylaws Amendment amended Section 2.5 of ARTICLE II of the Bylaws to reduce the quorum requirement for all meetings of stockholders of the Company from a majority of the voting power of the outstanding shares of the Corporation entitled to vote generally in the election of directors to one third of the voting power of the outstanding shares of the Corporation entitled to vote generally in the election of directors. The foregoing description of the Bylaws Amendment is qualified in its entirety by reference to the full text of the Bylaws Amendment, a copy of which is filed with this Current Report on Form 8-K as Exhibit 3.1.
01 Financial
Item 9.01 Financial (d) Exhibits The following exhibits are being filed herewith: Exhibit No. Document 3.1 Amendment to Second Amended and Restated Bylaws of Ocugen, Inc. 104 Cover Page Interactive Date File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 20, 2024 OCUGEN, INC. By: /s/ Shankar Musunuri Name: Shankar Musunuri Title: Chairman, Chief Executive Officer, & Co-Founder